Genomic Tests

Machine/deep Learning meets Next Generation Sequencing

Next Generation Sequencing DNA & RNA Testing

Next Generation Sequencing DNA & RNA Testing

Solid Tumors

Solid Tumor

Profile
434 Genes
  • TAT


    5-7 Days
  • Indications



    All solid tumors:
    Mutations in 434 genes,
    copy number variation and chromosomal structural abnormalities,
    TMB, MSI

    -
  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Solid Tumor Fusion /

Expression Profile
1400 Genes
  • TAT


    7-10 Days RNA
  • Indications

    ALL Solid tumors:
    Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 and other sarcoma genes
    Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
    ERBB2, MDM2
    Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
    Mutations in all 1400 genes
  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Solid Tumor

Profile Plus
434/1400 Genes
  • TAT

    5-7 Days DNA
    7-10 Days RNA
  • Indications


    ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
    MET exon 14 skipping and various alternative splicing,
    MET, HER2,
    EGFR amplification,
    PIK3CA, PTEN, AKT1 and RAS

    -
  • Sample Type

    FFPE
  • Sample Requirements


    1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA+RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching
PLUS

Solid Tumor

Monitoring
275 Genes
  • TAT


    5-7 Days DNA
  • Indications





    Monitoring therapy,
    resistance and relapse



    -
  • Sample Type

    Peripheral blood
  • Sample Requirements



    Peripheral blood: 5-10 ml.
    EDTA tube preferred
  • Results Reported

    DNA
  • Monitoring
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching
Liquid Biopsy

Hematology

Hematology

Profile
177 Genes
  • TAT


    5-7 Days
  • Indications




    MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases

    -
  • Sample Type

    Bone Marrow,
    Peripheral blood,
    Fresh tissue
  • Sample Requirements

    Bone marrow: 2ml.
    Peripheral blood: 5 ml.
    EDTA tube preferred
    FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Liquid Biopsy

Hematology Profile
177 Genes
  • TAT


    5-7 Days DNA
  • Indications





    cfDNA - MDS, CMML, AML, MPN, lymphoma, MRD


    -
  • Sample Type



    Peripheral blood
  • Sample Requirements




    Peripheral blood: 5-10 ml.
    EDTA tube preferred
    -
  • Results Reported

    DNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Hematology Fusion /

Expression Profile
1400 Genes
  • TAT


    7-10 Days RNA
  • Indications

    ALL hematologic neoplasms:
    Fusion: BCR-ABL1, FIP1L1-PDGFRA, ETV6-RUNX1, PML-RARA, RUNX1-RUNX1T1, ALL-Ph-Like fusions
    Expression: PD-L1, B-cell markers, T-cell markers, myeloid markers, KI67, MYC, BCL2, BCL6, BCL1, BCMA, PAX5
    alternative splicing, Mutations in all 1400 genes
  • Sample Type

    Bone Marrow,
    Peripheral blood,
    Fresh tissue
  • Sample Requirements

    Bone marrow: 2ml.
    Peripheral blood: 5 ml.
    EDTA tube preferred
    FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching

Hematology

Profile Plus
177/1400 Genes
  • TAT

    5-7 Days DNA
    7-10 Days RNA
  • Indications



    Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia,


    -
  • Sample Type

    Bone Marrow,
    Peripheral blood,
    Fresh tissue
  • Sample Requirements

    Bone marrow: 2ml.
    Peripheral blood: 5 ml.
    EDTA tube preferred
    FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
  • Results Reported

    DNA+RNA
  • Diagnostic
  • Therapeutic
  • Prognostic
  • Heterogeneity
  • Clinical Trial Matching
PLUS